MITOPE Trial

The MITOPE trial is now opened in the Queen Elizabeth University Hospital.

This clinical trial offers a new treatment option for MPE and mesothelioma patients using RS Oncology’s novel drug known as RSO-021. This new drug targets a specific mitochondrial enzyme (PRX3) by regulating oxidative stress to eliminate cancer cells while sparing normal cells. RSO-021 is administered weekly locally into the pleural cavity using an intrapleural catheter immediately after the pleural effusion is drained.

This clinical trial is available to patients who are at least 18 years old suffering from MPE and/or mesothelioma, and have documented tumor progression after receiving at least one prior standard of care treatment.  The trial will also soon be widening to include patients who had not had any treatment as a first line option.

For more information please contact carolyn.macrae@ggc.scot.nhs.uk